Evidence map›Paper›PMID 41497890›Full record

ArticleBreast cancer (Dove Medical Press)2025

Integrated Pan-Cancer Profiling and Breast Cancer Validation Identify BEND3 as a Potential Prognostic and Immune Biomarker.

Yuting Gou, Yongxiang Li, Yiyang Wang, Haotian Ma, Haocong Li, Reyima Geni, Dilimulati Ismtula, Chenming Guo

Abstract read
In one paragraph

Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Intratumoral PD-1Medical oncology (Northwood, London, England) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuting Gou *Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.
Yongxiang Li *Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.ORCID 0009-0001-6230-9594
Yiyang Wang *Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.
Haotian MaDepartment of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.
Haocong LiDepartment of Clinical Medicine, Xinjiang Medical University, Urumqi, People's Republic of China.
Reyima GeniDepartment of Clinical Medicine, Xinjiang Medical University, Urumqi, People's Republic of China.
Dilimulati IsmtulaDepartment of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.
Chenming GuoDepartment of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.ORCID 0000-0002-4531-8958

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: BEND3 is implicated in various physiological processes, including chromatin regulation, cell cycle regulation, etc.; nonetheless, its function in cancer is not well comprehended. Methods: Using public databases including UCSC Xena, TCGA, GTEx, and GEO, we conducted a comprehensive pan-cancer analysis to evaluate the clinical relevance of BEND3 across 33 cancer types. We analyzed genetic alterations, copy number variations (CNVs), and methylation profiles of BEND3, and explored its associations with tumor mutational burden (TMB), microsatellite instability (MSI), immune checkpoint molecules, and the tumor immune microenvironment. A protein-protein interaction (PPI) network and functional enrichment analysis were performed to investigate potential molecular mechanisms. In vitro, BEND3 expression was assessed by immunohistochemistry (IHC), Western blot (WB), and qRT-PCR. Cell Counting Kit-8 (CCK-8), colony formation, and wound healing assays were performed to validate BEND3's oncogenic role in breast cancer cell lines. Results: Our results show that BEND3 is frequently overexpressed in multiple cancers, including breast, liver, lung, thyroid, and gastric cancers, among others, and is associated with poor prognosis. Its expression correlates with TMB, MSI, immune checkpoint molecules, and immunoinfiltration, suggesting a role in tumor immunity. Functional analysis indicates involvement in key cancer-related pathways. In breast cancer, BEND3 was upregulated in clinical tissues and cell lines, and in vitro experiments demonstrated that BEND3 overexpression promoted the proliferation, migration, and invasion of breast cancer cells, whereas its knockdown suppressed these phenotypes. Conclusion: Our findings suggest BEND3 is a potential prognostic and immune-related cancer biomarker. Its overexpression in multiple cancers, association with poor survival, and role in tumor immunity support its oncogenic function. Functional analysis indicates it may regulate key cancer pathways. Importantly, in vitro experiments confirm its tumor-promoting effects in breast cancer, providing a foundation for further study of BEND3's mechanisms and therapeutic implications.

Indexed as

BEND3methylationpan-cancerprognosistumor immunity

Identifiers

PMID41497890
PMCPMC12766032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.